PureTech Health (NASDAQ:PRTC) today announced its financial results for the fiscal year ended December 31, 2025, alongside an update on its liquidity position for the first quarter of 2026.
The Boston-based clinical-stage biotherapeutics company ended 2025 with consolidated cash, cash equivalents, and short-term investments of $277.3 million, providing a stable financial foundation that management expects will fund operations at least through the end of 2028.
The past year was marked by significant clinical progress and a "sharpened focus" on capital efficiency.
PureTech successfully transitioned its lead program, deupirfenidone (for idiopathic pulmonary fibrosis), to Phase 3 readiness through its Founded Entity, Celea Therapeutics.
The company also reported positive clinical data for LYT-200 in myeloid malignancies and noted the continued maturation of Seaport Therapeutics’ neuropsychiatric pipeline.
In addition to its clinical updates, PureTech signaled a commitment to enhancing shareholder returns.
The board expressed an intention to return a greater proportion of future cash generation to investors, particularly in the event of outsized returns from its equity stakes in Founded Entities.
This move is paired with a planned Nasdaq delisting to consolidate trading volume on the London Stock Exchange, aimed at further streamlining the business.
Looking ahead to the remainder of 2026, PureTech is focused on the expected close of Celea’s external financing in the third quarter and the subsequent commencement of the Phase 3 SURPASS-IPF trial.
With a runway extending four years out and multiple late-stage catalysts on the horizon, the company remains positioned to unlock the value of its diversified hub-and-spoke R&D model.